Lista de obras -

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2017

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2017

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

artículo científico publicado en 2016

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

artículo científico publicado en 2018

A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer

artículo científico publicado en 2020

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma

scientific article published on 01 July 1996

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients

artículo científico publicado en 2018

A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer

scientific article published on 20 November 2006

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

artículo científico publicado en 2014

ASCO 2009: What's New in Breast Cancer Therapy?

artículo científico publicado en 2009

About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position

artículo científico publicado en 2019

Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations.

artículo científico publicado en 2017

Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?

artículo científico publicado en 2015

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).

artículo científico publicado en 2004

Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?

artículo científico publicado en 2009

Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)

article

Adjuvant systemic therapy for breast cancer

artículo científico publicado en 1996

Adjuvant therapy in elderly patients with breast cancer.

artículo científico publicado en 2004

An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

artículo científico publicado en 2003

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

artículo científico publicado en 2002

An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis

scientific article published on 01 December 1995

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

article

An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer

artículo científico publicado en 1994

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

artículo científico publicado en 2004

Breast cancer in the elderly: which lessons have we learned?

artículo científico publicado en 2013

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

artículo científico publicado en 1997

Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines

artículo científico publicado en 1993

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 pha

artículo científico publicado en 2017

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

artículo científico

Chemotherapy for metastatic breast cancer.

artículo científico publicado en 2004

Chemotherapy with or without trastuzumab.

artículo científico publicado en 2010

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials ⬇️

artículo científico publicado el 1 de noviembre de 2003

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

artículo científico publicado en 2019

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

artículo científico publicado en 1995

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

artículo científico

Control of emesis by a low dose of ondansetron and dexamethasone

scientific article published on 01 April 1994

Controversial issues in the management of older adults with early breast cancer.

artículo científico publicado en 2017

Controversies in the adjuvant treatment of breast cancer: the role of taxanes.

artículo científico publicado en 2004

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

artículo científico publicado en 2009

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

artículo científico publicado en 2017

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

artículo científico publicado en 2019

De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.

artículo científico publicado en 2017

Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes

artículo científico

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

artículo científico publicado en 2015

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

artículo científico publicado en 2002

Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial

artículo científico publicado en 2003

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

scientific article published on 05 August 2020

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer ⬇️

artículo científico publicado el 1 de noviembre de 2003

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

artículo científico publicado en 2014

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

artículo científico publicado en 2014

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants

artículo científico publicado en 2019

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

scientific article published on 16 July 2019

Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy

scientific article published on 01 June 2005

Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.

artículo científico publicado en 1995

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE

article

Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13).

artículo científico publicado en 2015

Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?

artículo científico publicado en 2012

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

artículo científico publicado en 2008

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

artículo científico publicado en 2013

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

artículo científico publicado en 2011

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

artículo científico publicado en 2012

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

artículo científico publicado en 2010

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study

artículo científico publicado en 2012

Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study

artículo científico publicado en 1997

HER2-positive metastatic breast cancer: a changing scenario

artículo científico publicado en 2015

HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology

scientific article published on 22 June 2019

Hormone therapy in advanced breast carcinoma: present and future trends.

artículo científico publicado en 1994

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

artículo científico publicado en 2011

Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medica

artículo científico publicado en 2019

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

artículo científico publicado en 2012

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

artículo científico publicado en 2017

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

scientific article published on December 2007

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

scientific article published on 10 December 2018

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

artículo científico publicado en 2003

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification

scientific article published on 29 August 2019

Metabolomics in breast cancer: A decade in review

article

Metabolomics: available results, current research projects in breast cancer, and future applications.

artículo científico publicado en 2007

Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group

artículo científico publicado en 1994

New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.

artículo científico publicado en 2007

No pain, no gain… What we can learn from a trial reporting negative results

artículo científico publicado en 2017

Nutritional management of older adults with gastrointestinal cancers: An International Society of Geriatric Oncology (SIOG) review paper.

artículo científico publicado en 2018

Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer

artículo científico publicado en 1998

Oral single-agent chemotherapy in older patients with solid tumours: A position paper from the International Society of Geriatric Oncology (SIOG).

artículo científico

Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over

artículo científico publicado en 2000

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial

artículo científico publicado en 2018

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial

scientific article published on 11 February 2019

Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

artículo científico publicado en 2016

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

scientific article published on 01 September 1996

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature

artículo científico publicado en 2018

Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002.

artículo científico publicado en 2002

Prognostic and predictive factors.

artículo científico publicado en 2009

Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)

scientific article published on 03 May 2019

Quality indicators in breast cancer care

artículo científico publicado en 2010

Quality indicators in breast cancer care: An update from the EUSOMA working group

artículo científico publicado en 2017

Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial

artículo científico publicado en 2019

Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization f

article

Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.

scientific article published on 03 April 2009

Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial.

artículo científico publicado en 2014

Screening for Frailty in Older Patients With Early-Stage Solid Tumors: A Prospective Longitudinal Evaluation of Three Different Geriatric Tools

artículo científico publicado en 2017

Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?

artículo científico publicado en 2007

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population

artículo científico publicado en 2017

Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.

artículo científico publicado en 2008

The best treatment for older patients with breast cancer.

artículo científico publicado en 2013

The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

scientific article published on 01 December 1997

The continued evidence from overviews: what is the clinical utility?

artículo científico publicado en 2013

The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned?

artículo científico publicado en 2000

The intramuscular administration of granulocyte colony-stimulating factor as an adjunct to chemotherapy in pretreated ovarian cancer patients: an Italian Trials in Medical Oncology (ITMO) Group pilot study.

artículo científico publicado en 1994

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review

artículo científico publicado en 2019

The role of abemaciclib in treatment of advanced breast cancer.

artículo científico publicado en 2018

Thyroid cancer: different outcomes to chemotherapy according to tumour histology

scientific article published on 01 December 1995

Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime?

artículo científico publicado en 2008

Toxicity profile differences of adjuvant docetaxel/cyclophosphamide (TC) between Asian and Caucasian breast cancer patients

artículo científico publicado en 2017

Trends in axillary lymph node dissection for early-stage breast cancer in Europe: Impact of evidence on practice

artículo científico publicado en 2019

Using specific cytotoxics with a targeted mind.

artículo científico publicado en 2007

Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey

scientific article published on 05 January 2019

Lista de obras de

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†

A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer

A dose-finding study of lanreotide (a somatostatin analog) in patients with colorectal carcinoma

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients

A joined analysis of two European Organization for the Research and Treatment of Cancer (EORTC) studies to evaluate the role of pegylated liposomal doxorubicin (Caelyx) in the treatment of elderly patients with metastatic breast cancer

A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial.

ASCO 2009: What's New in Breast Cancer Therapy?

About the French prohibition of textured breast implants: is it justified or over-cautious? The EUSOMA, ESSO/BRESSO position

Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations.

Adjuvant Systemic Therapy in Older Breast Cancer Women: Can We Optimize the Level of Care?

Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG).

Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more?

Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM)

Adjuvant systemic therapy for breast cancer

Adjuvant therapy in elderly patients with breast cancer.

An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.

An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.

An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project

An intensive treatment with mitoxantrone and ifosfamide in second-line therapy of epithelial ovarian cancer

Baseline health-related quality-of-life data as prognostic factors in a phase III multicentre study of women with metastatic breast cancer.

Breast cancer in the elderly: which lessons have we learned?

Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines

Cardiac safety, efficacy, and correlation of serial serum HER2-extracellular domain shed antigen measurement with the outcome of the combined trastuzumab plus CMF in women with HER2-positive metastatic breast cancer: results from the EORTC 10995 pha

Challenges in the management of advanced, ER-positive, HER2-negative breast cancer

Chemotherapy for metastatic breast cancer.

Chemotherapy with or without trastuzumab.

Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials ⬇️

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. Italian Trials in Medical Oncology

Continued value of adjuvant anthracyclines as treatment for early breast cancer.

Control of emesis by a low dose of ondansetron and dexamethasone

Controversial issues in the management of older adults with early breast cancer.

Controversies in the adjuvant treatment of breast cancer: the role of taxanes.

Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients.

Corrigendum to "3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259].

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer

De-escalating and escalating treatment beyond endocrine therapy in patients with luminal breast cancer.

Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypes

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial

Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial

EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer

EORTC Cancer in the Elderly Task Force guidelines for the use of colony-stimulating factors in elderly patients with cancer ⬇️

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

EUSOMA position regarding breast implant associated anaplastic large cell lymphoma (BIA-ALCL) and the use of textured implants

Early triple negative breast cancer: Are we getting better outcomes? A retrospective analysis from a single institution

Elderly breast cancer patients: adjuvant chemotherapy and adjuvant endocrine therapy

Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE

Estimating the risk of chemotherapy toxicity in older patients with cancer: The role of the Vulnerable Elders Survey-13 (VES-13).

Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients. Are we still missing the right screening tool?

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.

Final overall survival results and effect of prolonged (≥ 1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients.

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study

Glutamine supplementation in cancer patients receiving chemotherapy: a double-blind randomized study

HER2-positive metastatic breast cancer: a changing scenario

HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology

Hormone therapy in advanced breast carcinoma: present and future trends.

Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods

Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medica

Inter- and intra-tumoral heterogeneity in DNA damage evaluated by comet assay in early breast cancer patients

Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2- Advanced Breast Cancer?

Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification

Metabolomics in breast cancer: A decade in review

Metabolomics: available results, current research projects in breast cancer, and future applications.

Mitoxantrone and ifosfamide as second-line therapy of epithelial ovarian cancer. A pilot study by the I.T.M.O. Group

New strategies to identify molecular markers predicting chemotherapy activity and toxicity in breast cancer.